Company intelligence / Profile preview

METabolic Explorer

Ownership: Private
Employees: ~70
Development stage: Commercial

Overview

METabolic Explorer produces bulk chemical intermediates (such as 1,3-propanediol and butyric acid) by industrial fermentation, offering sustainable, low-carbon alternatives to petrochemical processes. While part of its manufacturing assets (Metex Nøøvistago) were acquired by Avril group in 2024, METabolic Explorer itself remains active, focused on commercializing its bio-based chemicals.

Industry: Non-Drug Biotech

Beyond the preview

Go deeper on METabolic Explorer.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on METabolic Explorer.

Explore the full profile